

GLAND PHARMA LIMITED

February 25, 2025

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245

National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051

Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Conclusion of US FDA Inspection at Company's JNPC Facility, Visakhapatnam

This is to inform you that the United States Food and Drug Administration (US FDA) has conducted a Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between February 19, 2025 and February 25, 2025.

The said inspection was concluded with THREE (3) Form 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.

The information required as per Regulation 30 read with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in Annexure A enclosed herewith.

Request to take the above information on record.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi **Company Secretary & Compliance Officer**

Encl: Annexure A



Annexure A

SI.	Particulars	Remarks
No 1	Name of the authority	United States Food and Drug Administration (US FDA)
2	Nature and details of the action(s) taken or order(s) passed;	Form 483 with Three (3) Observations
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Not Applicable
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	